Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer

Overview

Journal Bladder Cancer

Publisher IOS Press

Date 2018 Feb 13

PMID 29430504

Citations 18

Authors

Tilman Todenhofer

Werner J Struss

Roland Seiler

Alexander William Wyatt

Peter C Black

Affiliations

Soon will be listed here.

Abstract

Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide subsequent treatment selection. The potential utility of ctDNA in bladder cancer (BC) is bolstered by the high somatic mutation rate, meaning that very small numbers of genes or target regions can be informative. First reports indicate that analysis of ctDNA may represent a sensitive method for disease surveillance in patients with different stages of BC. Moreover, recent evidence suggests that ctDNA analysis reveals previously unknown genomic alterations in metastatic patients. Since some of these gene alterations represent therapeutic targets, ctDNA analysis provides an attractive tool to guide individualized therapy in BC.

Citing Articles

Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.

Lin Q, Serratore A, Niu J, Shen S, Roy Chaudhuri T, Ma W Drug Resist Updat. 2024; 73:101064.

PMID: 38387284 PMC: 11864563. DOI: 10.1016/j.drup.2024.101064.

An Investigation into Cell-Free DNA in Different Common Cancers.

Nafar S, Hosseini K, Shokrgozar N, Farahmandi A, Alamdari-Palangi V, Sichani A Mol Biotechnol. 2023; 66(12):3462-3474.

PMID: 38071680 DOI: 10.1007/s12033-023-00976-9.

Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.

Levy J, Chan N, Marotti J, Rodrigues N, Ismail A, Kerr D Cancer Cytopathol. 2023; 131(9):561-573.

PMID: 37358142 PMC: 10527805. DOI: 10.1002/cncy.22725.

Advanced Peptide Nanomedicines for Bladder Cancer Theranostics.

Zeng S, Feng X, Xing S, Xu Z, Miao Z, Liu Q Front Chem. 2022; 10:946865.

PMID: 35991612 PMC: 9389364. DOI: 10.3389/fchem.2022.946865.

Review of non-invasive urinary biomarkers in bladder cancer.

Lee H, Kim S Transl Cancer Res. 2022; 9(10):6554-6564.

PMID: 35117265 PMC: 8798424. DOI: 10.21037/tcr-20-1990.

References

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J . Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017; 9(403). PMC: 6714979. DOI: 10.1126/scitranslmed.aan2415. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Abbosh C, Birkbak N, Wilson G, Jamal-Hanjani M, Constantin T, Salari R . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655):446-451. PMC: 5812436. DOI: 10.1038/nature22364. View

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

Snyder M, Kircher M, Hill A, Daza R, Shendure J . Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016; 164(1-2):57-68. PMC: 4715266. DOI: 10.1016/j.cell.2015.11.050. View

Birkenkamp-Demtroder K, Nordentoft I, Christensen E, Hoyer S, Reinert T, Vang S . Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur Urol. 2016; 70(1):75-82. DOI: 10.1016/j.eururo.2016.01.007. View

Patel K, van der Vos K, Smith C, Mouliere F, Tsui D, Morris J . Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. Sci Rep. 2017; 7(1):5554. PMC: 5514073. DOI: 10.1038/s41598-017-05623-3. View

Alix-Panabieres C, Pantel K . Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016; 6(5):479-91. DOI: 10.1158/2159-8290.CD-15-1483. View

10.

Robertson A, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack A . Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017; 171(3):540-556.e25. PMC: 5687509. DOI: 10.1016/j.cell.2017.09.007. View

11.

Newman A, Lovejoy A, Klass D, Kurtz D, Chabon J, Scherer F . Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016; 34(5):547-555. PMC: 4907374. DOI: 10.1038/nbt.3520. View

12.

Wagle N, Grabiner B, Van Allen E, Hodis E, Jacobus S, Supko J . Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014; 4(5):546-53. PMC: 4122326. DOI: 10.1158/2159-8290.CD-13-0353. View

13.

. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View

14.

Liu D, Plimack E, Hoffman-Censits J, Garraway L, Bellmunt J, Van Allen E . Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016; 2(8):1094-6. PMC: 5515075. DOI: 10.1001/jamaoncol.2016.1056. View

15.

Savas P, Teo Z, Lefevre C, Flensburg C, Caramia F, Alsop K . The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". PLoS Med. 2016; 13(12):e1002204. PMC: 5189956. DOI: 10.1371/journal.pmed.1002204. View

16.

Teo M, Bambury R, Zabor E, Jordan E, Al-Ahmadie H, Boyd M . DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clin Cancer Res. 2017; 23(14):3610-3618. PMC: 5511570. DOI: 10.1158/1078-0432.CCR-16-2520. View

17.

Serizawa R, Ralfkiaer U, Steven K, Lam G, Schmiedel S, Schuz J . Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer. 2010; 129(1):78-87. DOI: 10.1002/ijc.25651. View

18.

Birkenkamp-Demtroder K, Christensen E, Nordentoft I, Knudsen M, Taber A, Hoyer S . Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. Eur Urol. 2017; 73(4):535-540. DOI: 10.1016/j.eururo.2017.09.011. View

19.

Thomsen M, Nordentoft I, Lamy P, Hoyer S, Vang S, Hedegaard J . Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Mol Oncol. 2016; 10(9):1450-1460. PMC: 5423216. DOI: 10.1016/j.molonc.2016.08.003. View

20.

Gust K, McConkey D, Awrey S, Hegarty P, Qing J, Bondaruk J . Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013; 12(7):1245-54. PMC: 3707970. DOI: 10.1158/1535-7163.MCT-12-1150. View